Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001178913-21-002810
Filing Date
2021-08-23
Accepted
2021-08-23 12:47:15
Documents
43
Period of Report
2021-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q zk2126393.htm   iXBRL 10-Q 756150
2 EXHIBIT 31.1 exhibit_31-1.htm EX-31.1 8119
3 EXHIBIT 32.1 exhibit_32-1.htm EX-32.1 4966
  Complete submission text file 0001178913-21-002810.txt   2822273

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE atms-20210630.xsd EX-101.SCH 27595
5 XBRL CALCULATION FILE atms-20210630_cal.xml EX-101.CAL 14942
6 XBRL DEFINITION FILE atms-20210630_def.xml EX-101.DEF 70444
7 XBRL LABEL FILE atms-20210630_lab.xml EX-101.LAB 150774
8 XBRL PRESENTATION FILE atms-20210630_pre.xml EX-101.PRE 135809
9 EXTRACTED XBRL INSTANCE DOCUMENT zk2126393_htm.xml XML 429194
Mailing Address 18 EAST 16TH STREET NEW YORK NY 10003
Business Address 18 EAST 16TH STREET NEW YORK NY 10003 646-233-1454
Artemis Therapeutics, Inc. (Filer) CIK: 0001062128 (see all company filings)

EIN.: 841417774 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-24431 | Film No.: 211196137
SIC: 2890 Miscellaneous Chemical Products